Roche's multiple sclerosis drug has shown success in clinical trials, with some outlets reporting it has met its main goal in at least one key trial. However, safety concerns have been raised, with reports of deaths and potential liver issues associated with the drug. The company is moving forward with regulatory submissions, but the outcome of the approval process is uncertain due to these lingering safety questions.